119136

Adenosine A1 Receptor Agonist II, CCPA

• 同義詞: Adenosine A1 Receptor Agonist II, CCPA
• 經驗公式（希爾表示法）: C₁₅H₂₀ClN₅O₄
• CAS號碼: 37739-05-2
• 分子量：: 369.80
• MDL號碼: MFCD00078574
• 分類程式碼代碼: 12352200

屬性

• 化驗: ≥99% (HPLC)
• 品質等級: 100
• 形狀: solid
• 效力: 2.3 nM K_i
• 製造商／商標名: Calbiochem^®
• 儲存條件: OK to freeze; protect from light
• 顏色: white
• 溶解度: DMSO: 100 mM; water: 5 mM
• 運輸包裝: ambient
• 儲存溫度: 2-8°C
• InChI: 1S/C15H20ClN5O4/c16-15-19-12(18-7-3-1-2-4-7)9-13(20-15)21(6-17-9)14-11(24)10(23)8(5-22)25-14/h6-8,10-11,14,22-24H,1-5H2,(H,18,19,20)/t8-,10-,11-,14-/m1/s1
• InChI 密鑰: XSMYYYQVWPZWIZ-IDTAVKCVSA-N

描述

一般說明

An adenosine analog that acts as a selective, high affinity agonist for Adenosine A1 receptor (A1R) (K_i = 800 pM; 2.3 µM, 18.8 µM, and 42 nM for human A1, A2A, A2B, A3 respectively). Shown to be centrally active following systemic administration and exhibits anti-convulsive effects. Also reported to inhibit adenylate cyclase activity in rat fat cell membrane (IC₅₀ = 33 nM). Diminishes respiratory rhythm, reduces heart rate, and enhances the activity of K_ATP channels. Reduces norepinephrine release by about 50% in untreated and pertussis toxin treated hearts.

生化／生理作用

Primary Target
A1

Reversible: yes

警告

Toxicity: Standard Handling (A)

重構

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

其他說明

Burgdorf, C. et al. 2005. J Cardiovasc Pharmacol.45, 1.
Klotz, K. N., et al. 2000. Naunyn Schmiedebergs Arch Pharmacol. 362, 382.
Mironov, S., et al. 1990. J Neurophysiol.81, 1.
Monopoli, A., et al. 1994.Arzneimittelforschung.44, 1305.
Concas, A., et al. 1993. J Pharmacol Exp Ther.267, 844.
Lohse, M. J., et al. 1988. Nauryn Schmiedebergs Arch Pharmacol.337, 687.
Coffin, V. L., et al. 1987. J Pharmacol Exp Ther.241, 76.

法律資訊

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

安全資訊

• 儲存類別代碼: 11 - Combustible Solids
• 水污染物質分類（WGK）: WGK 3
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable